| By Daiichi Sankyo |
| Friday, 24 April 2009 |
 |
Daiichi Sankyo Company, Limited, today obtained manufacturing and marketing approval in Japan for new formulations of Cravit® (generic name: Levofloxacin Hydrate), a broad-spectrum oral anti-bacterial agent. These formulations are 250mg and 500mg tablets, and a 10%
|
|
fine granular preparation. Since its introduction in December 1993, Cravit® has gained approval for treating 43 indications and 32 bacteria. This agent continues to offer outstanding efficacy, and has |
|
|
won accolades for its safety profile. Daiichi Sankyo drew on PK-PD theory (see note below) to develop the once-daily dosage for the 500mg Cravit® tablet.
This tablet lifts the maximum blood concentration and is significantly more bactericidal than the 100mg formulation, taken three times daily, suppressing the development of drug-resistant bacteria.
The once-daily dosage of the Cravit® 500mg tablet is an approved standard in more than 120 countries and territories. |
|
Daiichi Sankyo has accumulated years of expertise in the infectious diseases field, and is convinced that the Cravit® will contribute even more in treatment of infections.
Want to read more?
China Aoxing Pharmaceutical Company Receives GMP Certification For Tablet Dosage Form Of Pharmaceutical Products
Michael J. Graff and Mok Kwong Weng appointed to the Air Liquide Group Executive Committee
WaferGen Announces Signing of Private Financing |
|
|
